Lenvatinib (mesylate)

Lenvatinib is an inhibitor of the receptor tyrosine kinases VEGF receptor 2 (VEGFR2) and VEGFR3 (IC50s = 4 and 5.2 nM, respectively).1,2 It also inhibits the related kinases VEGFR1, FGFR1, PDGFRα, PDGFRβ and KIT (IC50s = 22, 46, 51, 39, and 100 nM, respectively).1 Lenvatinib (30 mg/kg, twice per day) reduces tumor growth in an H146 small cell lung cancer mouse xenograft model and induces tumor regression when administered at a dose of 100 mg/kg twice per day. Formulations containing lenvatinib have been used in the treatment of differentiated thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma.WARNING This product is not for human or veterinary use.

An inhibitor of VEGFR2 and VEGFR3

523.0

≥98%

Biochemicals/Kinase Inhibitors/FGFR Family/VEGFR Family/Small Molecule Inhibitors/Kinases

Formal_Name:4-[3-chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-6-quinolinecarboxamide, monomethanesulfonate;Synonyms:E-7080

COC(C(C(N)=O)=C1)=CC2=C1C(OC3=CC(Cl)=C(NC(NC4CC4)=O)C=C3)=CC=N2.CS(O)(=O)=O

C21H19ClN4O4 • CH3SO3H

857890-39-2

≥ 4 years

DMSO: 1mg/mL DMSO:PBS (pH 7.2) (1:5): 0.16mg/mL